newsfilter
← Latest News
GlobeNewswire·

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PYPD
  • PolyPid Ltd. will present Phase 3 SHIELD II trial data on D-PLEX 100 at the 45th Annual Meeting of the Surgical Infection Society on May 5-6, 2026, at the Coronado Island Marriott in California.
  • The presentation will focus on ASEPSIS score analysis demonstrating a statistically significant reduction in the severity of surgical wound infections following abdominal colorectal surgery.
  • Dr. Robert G. Sawyer, Professor & Chair of Surgery at Western Michigan University, will deliver the presentation titled "Evaluation of ASEPSIS Score as a Secondary Endpoint in the Phase 3 SHIELD II Trial."
  • Treatment with D-PLEX 100 combined with standard of care resulted in a 64% relative risk reduction (p=0.0103) in patients with an ASEPSIS score greater than 20 compared to standard of care alone.
  • CEO Dikla Czaczkes Akselbrad stated that D-PLEX 100 reduces surgical site infection events by 60% while making breakthrough infections less severe & complicated.
  • Potential benefits include fewer wound complications, reduced reliance on intravenous antibiotics, earlier hospital discharge, & lower hospital resource utilization costs.
  • D-PLEX 100 utilizes PolyPid's Kynatrix delivery technology to provide 30 days of prolonged doxycycline release directly at the surgical site.
  • The product received Breakthrough Therapy designation from the FDA for preventing SSIs in patients undergoing elective colorectal surgery.
  • The SHIELD II trial previously demonstrated a 60% (p=0.0013) relative risk reduction in SSI incidence for patients with large abdominal incisions.
  • The presentation is scheduled for Scientific Session III on Wednesday, May 6, 2026, from 8:00 a.m. to 9:00 a.m. PT.